candesartan cilexetil has been researched along with Chronic Disease in 13 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis." | 9.10 | Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. ( Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002) |
| "A Medline literature search was undertaken to identify randomised, controlled trials that examined the efficacy and cardiovascular outcomes associated with candesartan cilexetil in hypertension and chronic heart failure (CHF)." | 8.84 | Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. ( Meredith, PA, 2007) |
| "The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis focusing on major cardiovascular events and prospectively collected resource-use data from the CHARM-Added and CHARM-Alternative trials in patients with CHF and left ventricular (LV) systolic dysfunction." | 8.83 | Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. ( Keam, SJ; Plosker, GL, 2006) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 7.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| "The prevalence of heart failure is ever increasing around the world, particularly due to aging populations." | 6.45 | Candesartan cilexetil in the treatment of chronic heart failure. ( Baguet, JP; Barone-Rochette, G; Neuder, Y, 2009) |
| "In this prospective, parallel, open study of 86 patients with CGN, we compared the effects on proteinuria and renal functions of 36 months with comparable blood pressure (BP) control achieved by candesartan cilexetil (candesartan, 4-12 mg/day) or benazepril hydrochrolide (benazepril, 2." | 5.13 | Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. ( Fujiwara, H; Minatoguchi, S; Mori-Takeyama, U; Murata, I; Oda, H; Ohashi, H; Ohno, M; Ozaki, Y, 2008) |
| "A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis." | 5.10 | Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. ( Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002) |
| "A Medline literature search was undertaken to identify randomised, controlled trials that examined the efficacy and cardiovascular outcomes associated with candesartan cilexetil in hypertension and chronic heart failure (CHF)." | 4.84 | Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. ( Meredith, PA, 2007) |
| "The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis focusing on major cardiovascular events and prospectively collected resource-use data from the CHARM-Added and CHARM-Alternative trials in patients with CHF and left ventricular (LV) systolic dysfunction." | 4.83 | Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. ( Keam, SJ; Plosker, GL, 2006) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 3.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| "The prevalence of heart failure is ever increasing around the world, particularly due to aging populations." | 2.45 | Candesartan cilexetil in the treatment of chronic heart failure. ( Baguet, JP; Barone-Rochette, G; Neuder, Y, 2009) |
| "It was launched in 1998 for the treatment of hypertension." | 2.45 | Candesartan: widening indications for this angiotensin II receptor blocker? ( Mendis, B; Page, SR, 2009) |
| "Perindopril was stopped after the 8-week administration of the two drugs." | 1.32 | [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis]. ( Amemiya, M; Ando, Y; Asano, Y; Honma, S; Iimura, O; Kusano, E; Muto, S; Tanba, K; Yanagiba, S, 2003) |
| "These results suggest that, in polycythemia, enhanced NO production buffers the glomerular damage, and the balance between NO and angiotensin II may play an important role in maintaining renal function and glomerular structure." | 1.30 | Effects of chronic nitric oxide synthase inhibition on renal function and histology in polycythemic rats. ( Hashimoto, S; Kawata, T; Koike, T, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 11 (84.62) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sunami, E | 1 |
| Nomura, K | 1 |
| Nishiyama, Y | 1 |
| Katayama, Y | 1 |
| Baguet, JP | 1 |
| Barone-Rochette, G | 1 |
| Neuder, Y | 1 |
| Mendis, B | 1 |
| Page, SR | 1 |
| Kurokawa, K | 1 |
| Abe, K | 1 |
| Saruta, T | 2 |
| Arakawa, M | 1 |
| Kikkawa, R | 1 |
| Ueda, N | 1 |
| Onoyama, K | 1 |
| Tomita, K | 1 |
| Ogawa, N | 1 |
| Iimura, O | 1 |
| Kusano, E | 1 |
| Tanba, K | 1 |
| Yanagiba, S | 1 |
| Amemiya, M | 1 |
| Ando, Y | 1 |
| Honma, S | 1 |
| Muto, S | 1 |
| Asano, Y | 1 |
| Homma, K | 1 |
| Hayashi, K | 1 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 1 |
| Wakino, S | 1 |
| Fenton, C | 1 |
| Scott, LJ | 1 |
| Plosker, GL | 1 |
| Keam, SJ | 1 |
| Meredith, PA | 1 |
| Mori-Takeyama, U | 1 |
| Minatoguchi, S | 1 |
| Murata, I | 1 |
| Fujiwara, H | 1 |
| Ozaki, Y | 1 |
| Ohno, M | 1 |
| Oda, H | 1 |
| Ohashi, H | 1 |
| Tamura, Y | 1 |
| Kosuga, M | 1 |
| Yamashita, M | 1 |
| Tomioka, S | 1 |
| Sasaki, M | 1 |
| Hikita, T | 1 |
| Nakajima, H | 1 |
| Kojima, K | 1 |
| Uchida, S | 1 |
| Kawata, T | 1 |
| Hashimoto, S | 1 |
| Koike, T | 1 |
| Otsuka, F | 1 |
| Ogura, T | 1 |
| Yamauchi, T | 1 |
| Sato, M | 1 |
| Kataoka, H | 1 |
| Kageyama, J | 1 |
| Makino, H | 1 |
5 reviews available for candesartan cilexetil and Chronic Disease
| Article | Year |
|---|---|
Candesartan cilexetil in the treatment of chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Drug T | 2009 |
Candesartan: widening indications for this angiotensin II receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2009 |
Candesartan cilexetil: a review of its use in the management of chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart | 2005 |
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Cost o | 2006 |
Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
4 trials available for candesartan cilexetil and Chronic Disease
| Article | Year |
|---|---|
Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2002 |
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Benzimidazoles; Biphenyl Compounds; Bl | 2008 |
Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
4 other studies available for candesartan cilexetil and Chronic Disease
| Article | Year |
|---|---|
Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Arginine; Benzimidazoles; Biomarkers; | 2016 |
[Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2003 |
Effects of chronic nitric oxide synthase inhibition on renal function and histology in polycythemic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Enzy | 1998 |
Chronic treatment with angiotensin II type 1 receptor antagonist suppresses glomerular activator protein-1 activity in salt-sensitive hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |